Palvella Therapeutics, Inc.

Inventiva Restructures to Focus on MASH Drug Development, Reports €96.6M Year-End Cash Position

3 months ago

• Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction. • Company reports €96.6 million cash position at 2024 year-end, securing operations until Q3 2025, with potential additional funding of €116 million expected in Q2 2025. • Last patient screening completed in NATiV3 Phase 3 trial of lanifibranor, with final patient randomization expected in first half of 2025 and topline results anticipated in second half of 2026.

Palvella Therapeutics Advances QTORIN™ Rapamycin for Rare Genetic Skin Diseases

4 months ago

• Palvella Therapeutics' QTORIN™ rapamycin shows promise in treating microcystic lymphatic malformations (LMs), with Phase 2 results published in the Journal of Vascular Anomalies. • The Phase 2 study of QTORIN™ rapamycin demonstrated significant improvements in microcystic LMs, leading to the expansion of the Phase 3 SELVA trial to include children aged 3-5. • QTORIN™ rapamycin is also under evaluation in a Phase 2 trial (TOIVA) for cutaneous venous malformations, with first patients dosed, addressing a significant unmet need. • Both microcystic LMs and cutaneous VMs are rare genetic diseases with no FDA-approved therapies, and QTORIN™ rapamycin has the potential to become the first approved treatment.